VAL.L Stock - ValiRx plc
Unlock GoAI Insights for VAL.L
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $49,775 | $9,600 | N/A | N/A | N/A |
| Gross Profit | $-217,221 | $-246,043 | $-224,268 | $-228,789 | $-229,495 |
| Gross Margin | -436.4% | -2562.9% | N/A | N/A | N/A |
| Operating Income | $-2,141,671 | $-2,298,539 | $-2,593,379 | $-1,677,839 | $-1,650,625 |
| Net Income | $-1,915,693 | $-2,037,701 | $-2,406,164 | $-1,547,191 | $-1,468,323 |
| Net Margin | -3848.7% | -21226.1% | N/A | N/A | N/A |
| EPS | $-0.01 | $-0.02 | $-0.03 | $-0.02 | $-0.04 |
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a small molecule that has completed Phase I/II trials for the treatment of prostate cancer and other hormone associated solid tumours comprising breast and ovarian cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of women with endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc was incorporated in 2000 and is based in Hatfield, the United Kingdom.
Visit WebsiteEarnings History & Surprises
VAL.LEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Sep 25, 2025 | — | — | — | — |
Q2 2025 | May 29, 2025 | — | $-0.01 | — | — |
Q3 2024 | Sep 27, 2024 | — | $-0.01 | — | — |
Q2 2024 | May 15, 2024 | — | $-0.01 | — | — |
Q3 2023 | Aug 24, 2023 | — | $-0.01 | — | — |
Q2 2023 | Jun 14, 2023 | — | $-0.02 | — | — |
Q2 2022 | Jun 29, 2022 | — | $-0.02 | — | — |
Q4 2021 | Dec 30, 2021 | — | $-0.01 | — | — |
Q2 2021 | Jun 29, 2021 | — | $-0.01 | — | — |
Q4 2020 | Dec 30, 2020 | — | $-0.01 | — | — |
Q2 2020 | Jun 29, 2020 | — | $-0.04 | — | — |
Q4 2019 | Dec 30, 2019 | — | $-0.20 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-0.14 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-0.08 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-0.60 | — | — |
Q4 2017 | Dec 31, 2017 | — | $-0.30 | — | — |
Q2 2017 | Jun 30, 2017 | — | $-1.30 | — | — |
Q4 2016 | Dec 31, 2016 | — | $-0.65 | — | — |
Q2 2016 | Jun 30, 2016 | — | $-5.55 | — | — |
Q4 2015 | Dec 31, 2015 | — | $-4.05 | — | — |
Latest News
Frequently Asked Questions about VAL.L
What is VAL.L's current stock price?
What is the analyst price target for VAL.L?
What sector is ValiRx plc in?
What is VAL.L's market cap?
Does VAL.L pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to VAL.L for comparison